PARSIPPANY, NJ: Coyne PR has appointed Chris Cullmann, former SVP of digital strategy at Ogilvy CommonHealth Worldwide, to serve as director of digital strategy in the firm's health group.
Cullmann, who joined Coyne earlier this month, is reporting to Kelly Dencker, SVP and head of healthcare at the firm.
In the newly created role, Cullmann will expand the agency's digital practice capabilities, work with clients, and help with new business development. He will also incorporate his knowledge of healthcare communications and mobile health technologies into his client work.
Dencker said Cullmann's role is focused on where the market is going in terms of the convergence of different channels, such as traditional, digital, social media, and influencers.
Since digital is an emerging area at the agency, the firm brought on Cullmann because of his digital and brand strategy expertise, especially in the healthcare sector.
“The way we approach the business from the healthcare client space is really about helping them figure out their biggest challenges in this regulatory environment and being a strategist of how to make the most meaningful impact that can drive activation,” explained Dencker.
While working with various clients, Dencker said Cullmann will work on the Novartis business, which is focused on the company's Center of Excellence.
The healthcare group at Coyne has about 20 staffers, said Dencker.
Cullmann held various roles during his seven years at Ogilvy CommonHealth, including his most recent position of SVP. Before that, he served as a creative director for Ogilvy CommonHealth Interactive Marketing for two years, and he also spent three years at Qi Interactive, part of CommonHealth, serving as a group supervisor.
Previously, Cullmann was a senior web developer for Group DCA from 2003 to 2006. He also served as a senior web designer for Dentino Marketing from 1997 to 2003.
Throughout his career, Cullmann has worked on a number of digital projects for pharmaceutical companies, including Johnson & Johnson's Janssen, Novartis, Merck, GSK, Bayer, and Pfizer.
Earlier this summer, Coyne also appointed Todd Forte to serve as a VP in its pharmaceutical practice.